Experimental drug could offer more weight loss than any drug now on the market, study finds

  • 📰 NBCNews
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 86%

France Nouvelles Nouvelles

France Dernières Nouvelles,France Actualités

The experimental drug, retatrutide, helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds, in a mid-stage clinical trial, the company says.

of retatrutide were similar to other weight loss medications, Skovronky said. Side effects from Ozempic and Wegovy, for example, include nausea, vomiting, diarrhea and constipation. Generally, people experience those side effects as they ramp up the dosage at the start of treatment, but the side effects usually go away after prolonged use.

Jastreboff agreed. Retatrutide could be an option for people who don’t respond well to other weight loss medications. Given its potency, it could also be useful for people who need to lose a substantial amount of weight, she said.“It is early days,” Skovronsky said. The company has started enrolling participants in a larger phase 3 clinical trial, which will include thousands of participants. The trial is expected to be completed in December 2025, according to. After that, if the results hold up, the drug would need to go through the FDA’s rigorous review process.

Skovronsky said he hopes that retatrutide could one day provide the same levels of weight loss seen with bariatric surgery.as well as decrease the risk of heart disease.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 10. in FR
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

France Dernières Nouvelles, France Actualités